Simvastatin Reduces Plasma Osteoprotegerin in Type 2 Diabetic Patients With Microalbuminuria

In summary, 18 weeks of low-dose simvastatin treatment reduced circulating OPG levels in type 2 diabetic patients with microalbuminuria but had no effect on VCAM-1 or ICAM.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2007-12, Vol.30 (12), p.3122-3124
Hauptverfasser:	Nellemann, Birgitte, Gormsen, Lars C, Dollerup, Jens, Schmitz, Ole, Mogensen, Carl E, Rasmussen, Lars M, Nielsen, Søren
Format:	Artikel
Sprache:	eng
Schlagworte:	Albuminuria - blood Atherosclerosis - prevention & control Biological and medical sciences Cardiovascular disease Cardiovascular diseases Cell adhesion & migration Complications and side effects Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - urine Diabetes. Impaired glucose tolerance Diabetic Angiopathies - prevention & control Diabetic Nephropathies - blood Diabetic Nephropathies - drug therapy Dosage and administration Double-Blind Method Drug therapy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Enzyme-Linked Immunosorbent Assay Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Male Medical research Medical sciences Metabolic diseases Miscellaneous Osteoprotegerin - blood Proteins Public health. Hygiene Public health. Hygiene-occupational medicine Risk factors Simvastatin Simvastatin - therapeutic use Studies Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In summary, 18 weeks of low-dose simvastatin treatment reduced circulating OPG levels in type 2 diabetic patients with microalbuminuria but had no effect on VCAM-1 or ICAM.
ISSN:	0149-5992 1935-5548
DOI:	10.2337/dc07-0919